SCHEMBL4073889

SCHEMBL4073889

CCN(CC)CCN(Cc1cc2ccc(OC)cc2[nH]c1=O)C(=S)Nc1ccc(F)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.66
HSD17B10 Q99714 4/20 0.66
NSD2 O96028 1/20 0.66
POLB P06746 1/20 0.66
MPO P05164 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.57
ALDH1A1 P00352 9/20 0.56
LMNA P02545 5/20 0.56
GUSB P08236 2/20 0.56
MAPT P10636 3/20 0.55
RAB9A P51151 1/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
MAPK1 P28482 1/20 0.53
HSP90AA1 P07900 1/20 0.53
GAA P10253 1/20 0.52
PKM P14618 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4079416 0.81 KDM4E (0.84) KDM4EHSD17B10NSD2POLBMPO
SCHEMBL4069455 0.78 ALDH1A1 (0.64) KDM4EHSD17B10ALDH1A1LMNAGUSB
SCHEMBL4072881 0.77 MAPT (0.72) KDM4EHSD17B10NSD2POLBALDH1A1
SCHEMBL5453758 0.76 KDM4E (0.69) KDM4EHSD17B10POLBALDH1A1LMNA
SCHEMBL13496398 0.74 KDM4E (0.77) KDM4EHSD17B10NSD2POLBALDH1A1
SCHEMBL4079401 0.74 MPO (0.82) KDM4EHSD17B10POLBMPOALDH1A1
SCHEMBL13496395 0.72 ALDH1A1 (0.73) KDM4EHSD17B10POLBALDH1A1LMNA
SCHEMBL14300067 0.71 GUSB (1.00) KDM4EALDH1A1LMNAGUSBMAPT
SCHEMBL18270621 0.69 GUSB (1.00) KDM4EHSD17B10ALDH1A1LMNAGUSB
SCHEMBL13496397 0.68 GUSB (0.80) KDM4EHSD17B10ALDH1A1GUSBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG KDM4E 2403/4885HSD17B10 1580/4885NSD2 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.